[{"symbol": "AXSM", "publishedDate": "2026-01-16 12:15:13", "publisher": "Zacks Investment Research", "title": "Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia", "image": "https://images.financialmodelingprep.com/news/axsome-therapeutics-begins-phase-iii-study-on-axs14-for-20260116.jpg", "site": "zacks.com", "text": "AXSM doses the first patient in the phase III FORWARD study testing AXS-14 for fibromyalgia.", "url": "https://www.zacks.com/stock/news/2818973/axsome-therapeutics-begins-phase-iii-study-on-axs-14-for-fibromyalgia?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2818973"}, {"symbol": "AXSM", "publishedDate": "2026-01-15 10:51:26", "publisher": "Zacks Investment Research", "title": "Why Axsome Therapeutics (AXSM) is a Top Momentum Stock for the Long-Term", "image": "https://images.financialmodelingprep.com/news/why-axsome-therapeutics-axsm-is-a-top-momentum-stock-20260115.jpg", "site": "zacks.com", "text": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.", "url": "https://www.zacks.com/stock/news/2818116/why-axsome-therapeutics-axsm-is-a-top-momentum-stock-for-the-long-term?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|zacks_education_momentum_score-2818116"}, {"symbol": "AXSM", "publishedDate": "2026-01-12 16:20:00", "publisher": "Seeking Alpha", "title": "MoneyShow's Best Investment Ideas For 2026: Part 2", "image": "https://images.financialmodelingprep.com/news/moneyshows-best-investment-ideas-for-2026-part-2-20260112.jpg", "site": "seekingalpha.com", "text": "MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 2 of this series includes Axsome Therapeutics, Berkshire Hathaway, Blackstone, Cal-Maine Foods, and Cassiar Gold Corp., among others.", "url": "https://seekingalpha.com/article/4858926-moneyshow-best-investment-ideas-for-2026-part-2"}, {"symbol": "AXSM", "publishedDate": "2026-01-12 07:00:00", "publisher": "GlobeNewsWire", "title": "Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue", "image": "https://images.financialmodelingprep.com/news/axsome-therapeutics-provides-preliminary-fourth-quarter-and-full-year-20260112.jpg", "site": "globenewswire.com", "text": "Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively", "url": "https://www.globenewswire.com/news-release/2026/01/12/3216700/33090/en/Axsome-Therapeutics-Provides-Preliminary-Fourth-Quarter-and-Full-Year-2025-Net-Product-Revenue.html"}, {"symbol": "AXSM", "publishedDate": "2026-01-09 12:40:48", "publisher": "Zacks Investment Research", "title": "HALO or AXSM: Which Is the Better Value Stock Right Now?", "image": "https://images.financialmodelingprep.com/news/halo-or-axsm-which-is-the-better-value-stock-20260109.jpg", "site": "zacks.com", "text": "Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Axsome Therapeutics (AXSM). But which of these two stocks offers value investors a better bang for their buck right now?", "url": "https://www.zacks.com/stock/news/2815166/halo-or-axsm-which-is-the-better-value-stock-right-now?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_3-2815166"}, {"symbol": "AXSM", "publishedDate": "2026-01-08 08:23:23", "publisher": "MarketBeat", "title": "Biotech Is Heating Up\u2014These 2 Red-Hot Stocks Stand Out", "image": "https://images.financialmodelingprep.com/news/biotech-is-heating-upthese-2-redhot-stocks-stand-out-20260108.jpg", "site": "marketbeat.com", "text": "Biotech companies provide the medical innovations and technological breakthroughs that improve healthcare and can achieve tremendous financial results in the process. However, these names also tend to be highly volatile as a result of the difficult and complex process associated with drug and medical device development as well as the hard-to-navigate regulatory environment.", "url": "https://www.marketbeat.com/stock-ideas/biotech-is-heating-upthese-2-red-hot-stocks-stand-out/"}, {"symbol": "AXSM", "publishedDate": "2026-01-08 05:15:00", "publisher": "The Motley Fool", "title": "2 Healthcare Stocks to Buy for 2026 and Beyond", "image": "https://images.financialmodelingprep.com/news/2-healthcare-stocks-to-buy-for-2026-and-beyond-20260108.jpg", "site": "fool.com", "text": "Axsome Therapeutics and Exelixis are generating solid revenue with their current lineups. Both have promising late-stage candidates that should allow them to expand their portfolios.", "url": "https://www.fool.com/investing/2026/01/08/2-healthcare-stocks-to-buy-for-2026-and-beyond/"}, {"symbol": "AXSM", "publishedDate": "2026-01-05 07:04:55", "publisher": "Defense World", "title": "Stanley Laman Group Ltd. Makes New $2.13 Million Investment in Axsome Therapeutics, Inc. $AXSM", "image": "https://images.financialmodelingprep.com/news/stanley-laman-group-ltd-makes-new-213-million-investment-20260105.png", "site": "defenseworld.net", "text": "Stanley Laman Group Ltd. acquired a new position in Axsome Therapeutics, Inc. (NASDAQ: AXSM) during the third quarter, according to its most recent 13F filing with the SEC. The firm acquired 17,501 shares of the company's stock, valued at approximately $2,125,000. Other institutional investors have also modified their holdings of the company. Ameritas", "url": "https://www.defenseworld.net/2026/01/05/stanley-laman-group-ltd-makes-new-2-13-million-investment-in-axsome-therapeutics-inc-axsm.html"}, {"symbol": "AXSM", "publishedDate": "2026-01-03 05:17:03", "publisher": "Defense World", "title": "Axsome Therapeutics (NASDAQ:AXSM) Director Mark Saad Sells 37,577 Shares", "image": "https://images.financialmodelingprep.com/news/axsome-therapeutics-nasdaqaxsm-director-mark-saad-sells-37577-shares-20260103.png", "site": "defenseworld.net", "text": "Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) Director Mark Saad sold 37,577 shares of Axsome Therapeutics stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $165.18, for a total value of $6,206,968.86. Following the completion of the transaction, the director directly owned 10,002 shares", "url": "https://www.defenseworld.net/2026/01/03/axsome-therapeutics-nasdaqaxsm-director-mark-saad-sells-37577-shares.html"}, {"symbol": "AXSM", "publishedDate": "2026-01-02 11:55:19", "publisher": "Zacks Investment Research", "title": "AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation", "image": "https://images.financialmodelingprep.com/news/axsm-up-on-fda-priority-review-to-axs05-snda-20260102.jpg", "site": "zacks.com", "text": "Axsome stock jumps as the FDA grants priority review to sNDA for AXS-05 in Alzheimer's agitation, with a decision expected April 30, 2026.", "url": "https://www.zacks.com/stock/news/2811323/axsm-up-on-fda-priority-review-to-axs-05-snda-in-alzheimer-s-agitation?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2811323"}]